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Abstract
Background Substrate mapping has highlighted the importance of targeting diastolic conduction channels and late potentials
during ventricular tachycardia (VT) ablation. State-of-the-art multipolar mapping catheters have enhanced mapping capabilities.
The purpose of this study was to investigate whether long-term outcomes were improved with the use of a HD Grid mapping
catheter combining complementary mapping strategies in patients with structural heart disease VT.
Methods Consecutive patients underwent VT ablation assigned to either HD Grid, Pentaray, Duodeca, or point-by-point (PbyP)
RF mapping catheters. Clinical endpoints included recurrent anti-tachycardia pacing (ATP), appropriate shock, asymptomatic
non-sustained VT, or all-cause death.
Results Seventy-three procedures were performed (33 HD Grid, 22 Pentaray, 12 Duodeca, and 6 PbyP) with no significant
difference in baseline characteristics. Substrate mapping was performed in 97% of cases. Activation maps were generated in 82%
of HD Grid cases (Pentaray 64%; Duodeca 92%; PbyP 33% (p = 0.025)) with similar trends in entrainment and pace mapping.
Elimination of all VTs occurred in 79% of HD Grid cases (Pentaray 55%; Duodeca 83%; PbyP 33% (p = 0.04)). With a mean
follow-up of 372 ± 234 days, freedom from recurrent ATP and shock was 97% and 100% respectively in the HD Grid group
(Pentaray 64%, 82%; Duodeca 58%, 83%; PbyP 33%, 33% (log rank p = 0.0042, p = 0.0002)).
Conclusions This study highlights a step-wise improvement in survival free from ICD therapies as the density of mapping
capability increases. By using a high-density mapping catheter and combining complementary mapping strategies in a strict
procedural workflow, long-term clinical outcomes are improved.
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1 Introduction
Ventricular tachycardia (VT) ablation strategies for scar-
dependent monomorphic VT have evolved from traditional
entrainment and pace mapping to include activation and sub-
strate mapping with or without local abnormal ventricular activ-
ity (LAVA) potential and decrementing evoked potential
(DEEP) mapping in either paced or sinus rhythm [1, 2].
Substrate-guided approaches involve (1) the identification of
dense scar, borderzone (BZ), and areas of functional block; (2)
diastolic conduction channels (CC) identified with ripple map-
ping, voltage scanning, and/or DEEP potential mapping; and (3)
LAVA potential mapping [1, 3–6]. These approaches individu-
ally have been shown to improve long-term outcome [7].
Prerequisites of substrate-guided approaches include de-
tailed scar definition and mapping for near field low bipolar
voltage fractionated signals with relatively slow conduction
velocities, that help to define the VT site of origin and CCs
[8–10]. In practice, multiple substrate and VT isthmus defin-
ing approaches are used in any given case to define the VT
substrate, and long-term outcome data systematically combin-
ing these complementary approaches is lacking.
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More recently, state-of-the-art multi-electrode mapping
catheters have not only substantially decreased the time for
point acquisition but have also facilitated high-density map-
ping. In addition to increased resolution of the VT substrate,
multipolar mapping catheters have overcome the limitations
of point-by-point (PbyP) RF catheter mapping, with an in-
crease of near-field signals in the areas of interest and a de-
crease in far-field signals [11]. Increasing point density better
defines the VT substrate and multipolar mapping catheters not
only enhance map density but also provide wavefront direc-
tionality assessment [12, 13]. We have previously shown in
the Omnimapping study that the unique electrode and spacing
configuration of the Advisor HD Grid mapping catheter pro-
vides greater VT substrate definition of the BZ particularly at
the low-voltage range. This greater resolution within the low-
voltage range facilitates CC definition and quantification, es-
sential in guiding ablation strategy [6].
The purpose of this study was to investigate whether VT
ablation long-term outcomes were improved with the use of
high-density mapping combining complementary mapping
strategies into a strict mapping and ablation workflow.
2 Methods
Patients who underwent consecutive catheter ablation for VT
with structural heart disease from January 2016 to December
2019 at the University Hospital Coventry & Warwickshire
(UHCW) were included in this single center study. All adult
patients (≥ 18 years) were listed having been discussed at an
arrhythmia multidisciplinary team meeting. Clinical indica-
tions for VT ablation included symptomatic VT despite opti-
mized medical therapy, three or more episodes of VT within
24 h, at least 3 episodes of VT requiring anti-tachycardia pac-
ing (ATP), or at least one appropriate implantable cardiac
defibrillator (ICD) shock. All patients provided written con-
sent prior to the procedure. Approval for the study was pro-
vided by our Local Audit and Research Department. The
study applied the principles of the Declaration of Helsinki.
2.1 VT mapping protocol
All cases were first time procedures carried out according to a
strict UHCW VT ablation workflow (illustrated in Fig. 1)
which systematically applies multiple complimentary map-
ping strategies described in detail below and published previ-
ously [14]. All anti-arrhythmic drugs including amiodarone
were discontinued for at least 5 days prior to ablation if the
stability of arrhythmia allowed it. The procedure was per-
formed under deep sedation with direct arterial blood pressure
and oxygen saturation monitoring with selective procedures
performed under general anesthesia (GA) when procedural
risk was deemed high as a result of risk markers such as
concomitant respiratory disease, obesity, and/or LV ejection
fraction (EF) < 25%. Imaging was performed in all patients
prior to the procedure to rule out the presence of intra-cardiac
thrombus. All patients were administered intravenous
unfractionated heparin to maintain an activated clotting time
of ≥ 250 s prior to left ventricle (LV) access. Endocardial
access to the LV was obtained via transseptal access and ret-
rograde aortic approach in patients as previously described
[14]. Epicardial access was obtained in selected cases using
the Sosa sub-xiphoid approach with a Tuohy peridural needle
(Perican, Melsungen, Germany) prior to systemic
anticoagulation [15]. The pericardial puncture was guided by
a 90° left lateral fluoroscopic projection. The decision for an
epicardial approach was based on underlying heart condition,
the VT QRS morphology in a 12-lead ECG, failure of a prior
endocardial attempt to abolish the VT, or no dense confluent
scar revealed by endocardial voltage mapping. All arrhythmo-
genic right ventricular cardiomyopathy (ARVC) cases were
diagnosed using the International Task Force Criteria [16] and
underwent first time epicardial mapping.
Electro-anatomical substrate mapping was performed
using the EnSite NAVX/Velocity/Precision (Abbott
Medical, Inc., Minneapolis, MN) system or the CARTO
(Biosense Webster Inc., Diamond Bar, CA) system. Signals
were sampled at 1 kHz and filtered at 0.1 to 50 Hz for surface
ECGs and 30 to 250 Hz for intracardiac signals, displayed at
an amplification of 0.1 mV/cm. Mapping catheters used were
assigned by operator preference to include PbyP RF mapping
catheters (Tacticath (Abbott Medical, Inc., Minneapolis, MN),
Smart Touch (BiosenseWebster, Inc.)), and 3 multipolar cath-
eters: Livewire Duodeca (Abbott Medical, Inc., Minneapolis,
MN) which is a 20 electrode, 1 mm 2-2-2 interspacing linear
catheter; Pentaray NAV (Biosense Webster, Inc.); and
Advisor™ HD Grid mapping catheter (Abbott Medical, Inc.,
Minneapolis,MN). The Pentaray is a star-shaped catheter with
five flexible splines containing 20 electrodes. Two configura-
tions of the catheter are available with varying distances be-
tween the electrodes, 6-2-6 and 4-4-4 mm, and in this study,
all Pentaray cases were performed with the 4-4-4 mm config-
uration. The HD Grid has equidistant spacing of 16, 1 mm
electrodes in a 4 × 4, 3 mm interspaced arrangement. All HD
Grid cases were performed with the Wave configuration [6].
In endocardial cases, the large curve Agilis (St. Jude Medical,
St. Paul, MN) steerable sheath was used in combination with
the multipolar mapping catheters and the Epi-Agilis (St. Jude
Medical, St. Paul, MN) steerable sheath was used in all epi-
cardial cases.
Regular bipolar voltage definitions were used to describe
preserved myocardial voltage (> 1.5 mV), BZ voltage (0.5–
1.5 mV), and dense scar (< 0.5 mV) [17]. Electrograms
(EGMs) were classified according to the standard criteria
[18] as follows: (1) normal (≤ 3 sharp intrinsic deflections
from baseline, amplitude ≥3 mV, duration < 70 ms, and
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amplitude: duration > 0.046 mV/ms), (2) fractionated (multi-
ple intrinsic deflections, amplitude ≤ 0.5 mV, duration ≥
133 ms, and amplitude: duration ≤ 0.005 mV/ms), (3) late
(isolated component ≥ 20 ms after the end of surface QRS),
and (4) very late potentials (isolated component ≥ 100ms after
the end of surface QRS). CCs were defined as (1) conducting
corridors of voltage difference detected by “voltage scanning”
at different voltage thresholds within the scar area. The surface
bipolar voltage settings were adjusted by gradually reducing
the upper threshold cutoff from 1.5 to 0.5 mV in 0.02 mV
decrements. Below 0.5 mV, the difference in the upper and
lower voltage thresholds was altered keeping a 0.02 mV dif-
ference until complete loss of any voltage gradient was
achieved [3, 6]; (2) Decrementing evoked potential (DEEP)
channel mapping as previously described [9]. To nullify the
artifact of epicardial fat and coronary vasculature on epicardial
signals, we defined abnormal epicardial electrograms as sig-
nals with durations of > 80 ms, demonstrating fractionation
with ≥ 2 components, or demonstrating late potentials with
an onset well after the QRS [19].
If VT was hemodynamically stable, defined by a systolic
blood pressure greater than 90 mmHg, a conventional
activation map with a window of interest 90% of the VT cycle
length was constructed. When technically feasible, the activa-
tion map was turbo-mapped to generate a diastolic activation
map to define areas of slow conduction or with the use of
ripple mapping. This was followed by entrainment maneuvers
[20]. For hemodynamically unstable VT, limited activation
maps were attempted by placing the mapping catheter at po-
tential VT isthmus sites prior to VT induction protocols. If a
surface 12-lead ECG of the clinical VT was available pre- or
peri-procedure, pace mapping was performed with good
pacemaps defined as ≥ 11/12 matching leads or > 90% mor-
phology match.
2.2 Ablation parameters
Ablation was performed using either the Smart Touch ablation
catheter or the Tacticath ablation catheter. All PbyP mapping
cases were performed with either the Smart Touch or
Tacticath ablation catheters. The Smart Touch ablation cathe-
ter was used in all Pentaray mapping cases. The Tacticath
ablation catheter was used in all Duodeca and HD Grid map-
ping cases. Importantly, ablation parameters were kept
Fig. 1 Patient with ischemic cardiomyopathy. VT tachycardia cycle
length (TCL) 380 ms mapped using HD Grid. a Endocardial LV
substrate map demonstrates posterior wall scar with heterogeneous scar
extending towards the septum. Voltage scanning (0.155 mV) identifies a
CC extending from the septal BZ into the posterior dense scar region.
DEEP potentials tagged green. b Example DEEP potentials (asterisks)
identified with pacing from the right ventricular apex with 2 ventricular
sensed extra stimuli at 400 ms. c Clinical VT activation map: earliest
activation at septal BZ, and with HD Grid positioned at the
posteroseptal BZ (sold white arrow); d the entire diastolic isthmus
activation is localized to this region. HD Grid positioned with D-spine
posterior, A-spline septal, and EGMs show diastolic wavefront
propagation from posterior dense scar to inferoseptal BZ. e Pace
mapping at this site matches 12/12, 90% morphology match. Ablation
delivered to the posteroseptal BZ targeting the CC and VT isthmus (a
black tags). f Post-ablation substrate re-map confirms CC elimination and
homogenization of posteroseptal BZ. Complete procedural success. Pink
location tags in a, c, and f: VT “bump” termination with catheter
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consistent between cases with power titrated between 30 and
50 W and an irrigation rate up to 30 mL/min aiming for min-
imum impedance drops of 15 Ω/lesion. Force time integral
ranges were kept between 300 and 400. Ablation targets were
limited to CCs and clinical VT critical isthmus sites if entrain-
ment and activation mapping was performed. All epicardial
ablation was performed at 30 to 40 W irrigated RF, post-
coronary angiography to ensure ablation targets >1 cm from
major epicardial coronary arteries and phrenic nerves.
2.3 Post-ablation re-map
A key part of the UHCW VT ablation workflow is the sub-
strate re-map post-ablation using the index mapping catheter
to ensure substrate modification. Where viable myocardium
was detectable at ablation targets in the re-map, as per “volt-
age scanning” described above, further ablation was per-
formed to ensure complete substrate elimination. Post-
procedure unfractionated heparin was reversed with 50 mg
intravenous protamine and for epicardial cases 40 mg
triamcinolone/40 mg gentamicin was administered
intrapericardial prior to sheath removal.
2.4 Programmed electric stimulation
We used programmed electric stimulation (PES) from the right
ventricular apex and outflow tract with 2 different drive cycle
lengths (600 and 400ms) and introduction of up to 3 extrastimuli
until a ventricular effective refractory period or a coupling inter-
val of 200 ms was reached, without the use of isoproterenol.
Clinical VT was determined from the available 12-lead ECG
or VT cycle length in the ICD memory. All other monomorphic
VTs including polymorphic VT were deemed non-clinical. Far-
field EGM morphology was not routinely taken into consider-
ation to distinguish the VTmorphology. Non-clinical monomor-
phic and hemodynamically stable VTs inducible during the pro-
cedure were also targeted for ablation. Complete elimination of
any clinical and non-clinical monomorphic VT was defined as
complete success. Elimination of the clinical VT only with in-
ducible non-clinical monomorphic VT was defined as partial
success. Re-induction of clinical VT despite ablation was de-
fined as procedure failure. Major procedure-related complica-
tions were defined as those necessitating additional interventions
and leading to prolonged hospitalization.
2.5 Device re-programming and antiarrhythmic drug
therapy
To minimize bias, all ICDs were programmed post-procedure
according to a standardized protocol on the basis of the best
evidence available at the time of study initiation study [21]. In
addition, all patients remained on the previously ineffective
antiarrhythmic drug therapy after the procedure.
2.6 Clinical follow-up
Long-term follow-up was assessed from the first VT ablation
procedure until the latest documented clinical contact which
included ICD interrogation data. Patients were followed up at
1, 3, 6, and 12 months for the first year and every 6 months
thereafter. ICDs were interrogated at each visit, and arrhyth-
mia logs were retrieved. A detailed history, Holter monitoring,
and ECG were performed in symptomatic patients without
ICD shocks. VT recurrence was defined as any episode of
VT requiring ICD therapy (ATP or shock). Episodes of
asymptomatic non-sustained VT (NSVT) recorded from de-
vice interrogations were included in the analysis as well as all-
cause mortality.
2.7 Statistical analysis
Continuous variables are expressed as mean ± SD. Statistical
significance was assessed using the unpaired Student’s t test
or Mann-Whitney test if necessary. For the comparison of the
4 catheter groups, we used non-parametric Kruskal-Wallis test
to compare continuous variables. Categorical variables,
expressed as numbers or percentages, were analyzed using
the chi-square test, Fisher’s exact test, or McNemar test for
paired comparison. Univariate analysis of variables was per-
formed. Cumulative event rates were calculated according to
the Kaplan-Meier method. Hazard ratios with corresponding
95% confidence intervals (CIs) are presented. p value < 0.05
defined statistical significance. Statistical analysis was per-
formed using MedCalc and Statview 5.0 statistical software.
3 Results
On the basis of the above definitions, a total of 73 patients
underwent VT ablation with a mean total follow-up of 372 ±
234 days. A total of 33 procedures were performedwith the HD
Grid mapping catheter, 22 Pentaray, 12 Duodeca, and 6 PbyP
mapping cases. The baseline characteristics shown in Table 1
show no significant differences in gender, age, LVEF, or ische-
mic heart disease etiology between the 4 groups. Importantly,
there was a similar proportion of patients suffering with pre-
ablation ATP or appropriate shocks with no significant differ-
ence in number of baseline clinical VTs. There were no signif-
icant differences in co-morbidities or treatment with beta-
blockers and/or amiodarone between the 4 groups.
3.1 Procedural data
Procedural data recorded for each mapping catheter has been
summarized in Table 2. The majority of cases in all 4 groups
were performed under deep sedation with endocardial LV
mapping. There was no significant difference in the
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proportion of patients undergoing endocardial RV mapping.
All epicardial mapping cases were performed with multipolar
mapping catheters.
Substrate mapping was performed in 97% (71/73) of cases
with no significant difference between the 4 mapping groups.
There was no significant difference in the frequency of map-
pable hemodynamically stable VTs between the 4 groups;
however, activationmaps used to guide ablationwere success-
fully generated in 82% of HD Grid cases, 64% of Pentaray
cases, 92% Duodeca cases, and only 33% of RF mapping
cases (p = 0.025). A 2 × 2 analysis between groups showed
no difference between the HD Grid, Pentaray, or Duodeca
catheters; however, both HD Grid (p = 0.04) and Duodeca
(p = 0.04) were superior to PbyP RF catheter activation
mapping. A similar trend was observed with successful en-
trainment mapping. There was no significant difference in the
frequency of pace mapping performed between the 4 groups;
however, successful pacemaps used to guide ablation were
more likely to be obtained with the multipolar mapping cath-
eters (HD Grid 58%; Pentaray 45%, Duodeca 83%) than the
PbyP RF mapping group (17%; p = 0.039). Accordingly, a
greater number of VTs were mapped with multipolar catheters
and thereafter ablated. There was a trend towards a higher
number of VTs mapped and subsequently ablated in the HD
Grid and Pentaray groups.
The mean initial substrate mapping time of the chamber of
interest was shortest for the HD Grid compared to the
Pentaray, Duodeca, and PbyP RF groups (37 ± 10.9 min, 63
Table 1 Baseline clinical and
demographic characteristics of the
study population comparing HD
Grid, Pentaray, Duodeca, and











Male, n (%) 30 (91) 17 (77) 11 (92) 5 (83) 0.48
Age at ablation,
mean ± SD
68.7 ± 11.1 65.2 ± 11.0 72.9 ± 6.9 58.2 ± 16.4 0.05
Etiology Ischemic 24 (73) 17 (77) 7 (58) 3 (50) 0.46
DCM 5 (15) 3 (14) 1 (8) 2 (33) 0.57
HCM 0 2 (9) 3 (25) 0 0.03
ARVC 4 (12) 0 0 1 (17) 0.18
Other 0 0 1 (8) 0 0.16
ICD, n (%) 32 (97) 21 (95) 12 (100) 4 (67) 0.02
Pre-ablation ATP, n (%) 25 (76) 20 (91) 11 (92) 4 (67) 0.28
Pre-ablation shock, n (%) 22 (67) 20 (91) 12 (100) 4 (67) 0.07
AF, n (%) 11 (33) 8 (36) 8 (67) 1 (17) 0.13
Flutter, n (%) 0 0 1 (8) 0 0.16
Hypertension, n (%) 16 (48) 14 (64) 4 (33) 1 (17) 0.14
Diabetes Mellitus, n (%) 6 (18) 4 (18) 0 0 0.28
Stroke, n (%) 1 (3) 0 0 0 0.75
LV dysfunction, n (%) 30 (91) 20 (91) 11 (92) 5 (83) 0.94
Ejection Fraction 35.2 ± 11.6 32.3 ± 8.8 31.5 ± 11.5 34 ± 18.2 0.72
Beta-blocker, n (%) 33 (100) 21 (95) 11 (92) 6 (100) 0.43
Amiodarone, n (%) 25 (76) 19 (86) 8 (67) 5 (83) 0.57
Verapamil, n (%) 0 0 0 0 1
Sotalol, n (%) 0 0 0 0 1
Flecainide, n (%) 0 0 0 0 1
Mexilitine, n (%) 0 2 (9) 1 (8) 3 (50) 0.008
Anticoagulation, n (%) Warfarin 5 (15) 11 (50) 5 (42) 1 (33) 0.04
Apixaban 6 (18) 2 (9) 3 (25) 0 0.41
Edoxaban 2 (6) 0 8 0 0.56
Dabigatran 0 1 (4.5) 0 0 0.50
Rivaroxaban 4 (12) 1 (4.5) 0 0 0.40
Number of clinical VTs,
mean ± SD
1.39 ± 0.55 1.50 ± 0.86 1.08 ± 0.3 1.00 ± 0.00 0.14
DCM dilated cardiomyopathy, HCM hypertrophic cardiomyopathy, AVC arrhythmogenic cardiomyopathy, ICD
implantable cardiac defibrillator, ATP anti-tachycardia pacing, AF atrial fibrillation
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± 20.2 min, 55 ± 16 min, 96 ± 23.6 min; p < 0.001), with no
significant difference between the Pentaray and Duodeca
groups. Importantly, there was no difference in frequency of
LV or RV endocardial mapping between groups. The mean
number of maps constructed per case excluding the Precision
One Map and Turbomap functions was greatest in the HD
Grid group (2.3 ± 0.68; p < 0.001), with no significant differ-
ence between the Pentaray (1.3 ± 0.46) and Duodeca (1.5 ±
0.52) groups and the number of points used per map were
greater with HD Grid than any other mapping catheter.
There was a significantly greater duration of RF delivery in
the multipolar mapping groups than the PbyP RF group and
fluoroscopy times were similar between all 4 groups.
In terms of post-procedural endpoint testing, a significantly
greater number of clinical VTs were still inducible in the PbyP
RF mapping group (50%, p = 0.016) compared to the multi-
polar mapping catheters (HD Grid 3%, Pentaray 18%,
Duodeca 17%). Complete elimination of clinical and non-
clinical VTs was achieved in 79% of HD Grid, 55% of
Pentaray, 83% Duodeca, and 33% of PbyP RF mapping cases
(p = 0.04) with no statistical difference with comparative anal-
ysis between the HD Grid, Pentaray, or Duodeca cases.
There was no significant difference in complication rates
between the 4 groups. In total, 2 patients suffered pericardial
effusions, one of which required a pericardial drain. There
were 2 patients that suffered femoral vascular complications,
one with a groin hematoma, and one patient with a
pseudoaneurysm. One patient suffered pulmonary edema
and one patient developed left bundle branch block necessi-
tating device upgrade to biventricular pacing.










GA, n (%) 6 (18) 6 (27) 2 (17) 1 (17) 0.83
RV mapping, n (%) 7 (21) 3 (14) 3 (25) 1 (17) 0.71
LV mapping, n (%) 31 (94) 22 (100) 12 (100) 5 (83) 0.24
Endocardial mapping, n (%) 33 (100) 21 (95) 12 (100) 6 (100) 0.50
Epicardial mapping, n (%) 7 (21) 1 (4) 2 (16) 0 0.24
Epicardial access, n (%) 7 (21) 1 (4) 1 (8) 0 0.20
Pre-ablation PES, n (%) 9 (27) 5 (23) 6 (50) 5 (83) 0.02
VT hemodynamically stable, n (%) 18 (55) 12 (55) 8 (67) 3 (50) 0.88
VT CL ms, mean ± SD 364 ± 68 382 ± 86 371 ± 54 358 ± 65 0.91
Substrate map, n (%) 33 (100) 22 (100) 11 (92) 5 (83) 0.06
Activation map, n (%) 27 (82) 14 (64) 11 (92) 2 (33) 0.025
Pace map, n (%) 20 (61) 11 (50) 11 (92) 4 (67) 0.11
Pace map >11/12, n (%) 19 (58) 10 (45) 10 (83) 1 (17) 0.039
Entrainment map, n (%) 7 (21) 5 (23) 4 (33) 0 0.45
RF catheter Smart Touch, n (%) 0 22 (100) 0 4 (66) < 0.001
Tacticath, n (%) 33 (100) 0 12 (100) 2 (33) < 0.001
VTs induced/case, mean ± SD 2.1 ± 0.4 1.9 ± 1.1 1.8 ± 0.5 1.3 ± 0.8 0.11
VTs mapped, mean ± SD 1.5 ± 0.7 1.7 ± 1.46 1.25 ± 0.45 0.5 ± 0.5 0.06
VTs ablated, mean ± SD 1.4 ± 0.7 1.6 ± 1.46 1.25 ± 0.45 0.5 ± 0.5 0.09
Initial substrate map time (min), mean ± SD 37 ± 10.9 63 ± 20.2 55 ± 16 96 ± 23.6 < 0.001
Number of maps/case, mean ± SD 2.3 ± 0.68 1.3 ± 0.46 1.5 ± 0.52 1 ± 0 < 0.001
Mapping points/map, mean ± SD 2687 ± 2192 1426 ± 1192 1256 ± 892 207 ± 202 < 0.001
Post-procedure clinical VT inducible, n (%) 1 (3) 4 (18) 2 (17) 3 (50) 0.016
Post-procedure non-clinical VT inducible, n (%) 7 (21) 9 (41) 1 (8) 4 (67) 0.027
Elimination of all clinical & non-clinical VTs n,(%) 26 (79) 12 (55) 10 (83) 2 (33) 0.04
Complications, n (%) 2 (6) 2 (9) 1 (8) 1 (17) 0.68
RF total (min), mean ± SD 42 ± 19 62 ± 18 34 ± 18 29 ± 10 0.001
Fluoroscopy time (min), mean ± SD 34.5 ± 14 28.5 ± 8.3 31.9 ± 6.3 30.3 ± 11.3 0.31
Procedure time (min), mean ± SD 350 ± 105 261 ± 59 257 ± 74 239 ± 72 < 0.001
Post procedure echo, n (%) 33 (100) 21 (95) 12 (100) 6 (100) 0.50
GA general anesthesia, PES pulsed electrical stimulation, CL cycle length
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3.2 Long-term outcome
Figure 2 shows the event-free survival from (a) asymptomatic
NSVT, (b) ATP, (c) appropriate shocks, and (d) death in all 4
mapping catheter groups. There was no statistical difference in
asymptomatic NSVT. In terms of ATP (2b) and appropriate
ICD shock (2c), there was a step-wise improvement in event-
free survival from PbyP RF catheter mapping (33%ATP-free,
33% shock-free) to multipolar mapping with the Pentaray
(64% ATP-free, 82% shock-free) and Duodeca (58% ATP-
free, 83% shock-free) with the lowest event rates in the HD
Grid group (97% ATP-free, 100% shock-free). No difference
in mortality was observed.
There was a 96% relative reduction in device therapy for
ATP in the HD Grid group as 25/33 (76%) patients received
ATP pre-ablation compared to 1/33 (3%) at final follow-up. In
the Pentaray, Duodeca, and PbyP RF groups, 20/22 (91%),
11/12 (92%), and 4/6 (67%) patients received ATP pre-abla-
tion, compared to 8/22 (36%), 5/12 (42%), and 4/6 (67%) at
final follow-up; relative reductions of 60%, 55% and 0% re-
spectively (p = 0.004). An analysis of appropriate shocks
showed a 100% relative reduction in device therapy for ap-
propriate shock in the HD Grid group as 22/33 (67%) patients
received shock therapy pre-ablation compared to 0/33 at final
follow-up. In the Pentaray, Duodeca, and PbyP RF groups,
20/22 (91%), 12/12 (100%), and 4/6 (67%) patients received
shock therapy pre-ablation compared to 4/22 (18%), 2/12
(17%) and 4/6 (67%) at final follow-up; relative reductions
of 80%, 83%, and 0% respectively (p = 0.008). As shown in
Fig. 2b and c, time to first ATP therapy in the 4 groups were
33, 2, 9, and 87 days, respectively. There were no appropriate
shocks in the HDGrid group and time to first shock therapy in




This study shows that high density grid mapping combining
complementary mapping strategies for structural heart VT ab-
lation provides a significant advantage in long-term outcomes.
The rationale for this analysis, of comparing the unique ability
of the HD Grid mapping catheter to detect orthogonal low
amplitude voltages, was based on our previous reports of an
increase in CCs identifiable when compared to a high density
linear multipolar catheter configuration [6]. The main findings
of this study are (1) multipolar mapping catheters facilitate
mapping an increased number of hemodynamically stable
Fig. 2 Kaplan-Meir curves of all 4 mapping catheters showing event free survival from a asymptomatic NSVT, b anti-tachycardia pacing (ATP), c
appropriate shock, and d death
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and unstable VTs compared to PbyP RF catheter mapping, (2)
the greater number of VTs mapped with the HD Grid catheter
corresponds to an increased number of clinical and non-
clinical VTs ablated, (3) the high-density maps created with
the HD Grid catheter correlates not only with improved pro-
cedural endpoints but with long-term clinical outcomes, and
(4) HD Grid mapping provides an advantage in long-term
survival free of ICD therapies.
4.2 Diversity of multipolar mapping
An important determinant of successful VT ablation is an
informative substrate map and we have shown the capability
of multipolar and PbyP RF catheters in generating an initial
substrate map with significant differences in map construct
time. The time taken to generate an initial substrate map with
the HD Grid catheter was 37 ± 10.9 mins compared to 96 ±
23.6 with PbyP RF catheters (p < 0.001). Our experience with
the Pentaray suggests that the irritability of the 5 open-ended
splines can result in longer map times due to the requirement
of a 95% sinus rhythm or paced rhythm morphology template
(identical set-up with HD Grid and Duodeca cases). A previ-
ous study in structural heart VT patients demonstrated similar
map times of 55.6 ± 34.4min with the Pentaray [22]. Despite a
shorter initial substrate mapping time, the procedural time was
significantly longer in the HD Grid group compared to other
mapping catheters due to a combination of factors. There was
a trend towards a greater number of clinical VTs and VTs
inducible in the multipolar mapping catheter groups, an in-
crease in RF time in the HD Grid group compared to the
PbyP and Duodeca groups and almost twice as many maps
per case constructed with the HD Grid group compared to all
other mapping catheters. In addition, the initial cases per-
formed with HD Grid involved a learning curve which result-
ed in the prolonged procedure times substantiated by the larg-
er standard deviation 350 ± 105 mins.
We have shown a clear distinction in the ability of multi-
polar mapping catheters to generate “usable” activation maps.
This requires the catheter to be manipulated rapidly during VT
with the acquisition of point density sufficient enough to de-
fine the VT isthmus, which can be compromised with limited
point acquisition with PbyP RF catheter mapping.
Furthermore, the ability of pacemapping to be performed from
multiple sites without having to manipulate the multipolar
mapping catheter may explain why these catheters were more
effective in generating good pacemaps when compared to
PbyP RF catheters. It has previously been shown that the
use of multipolar catheters to focus high-density mapping is
an independent predictor of VT-free survival [23, 24].
Importantly, the multipolar mapping catheter used in these
previous studies was the Pentaray and our study highlights
the additional benefits of mapping with the HD Grid.
A key part of the UHCW VT ablation workflow is the re-
map performed post-ablation to ensure substrate elimination.
The increased number of maps constructed per case with the
HD Grid catheter emphasizes its advantage in this regard in
terms of speed and detail of map construction to guide further
ablation if necessary. It is plausible that the process of re-
mapping to further target abnormal electrograms may have
in part contributed to the improved outcomes of the HD
Grid catheter.
4.3 Impact on procedural endpoints and long-term
clinical outcomes
Successful elimination of all clinical and non-clinical VTs was
more likely to be achieved with ablation guided by multipolar
mapping catheters. The improvement in ICD outcomes in the
HD Grid group compared with the Pentaray and DuoDeca
groups appears to have been driven by the near absence of
clinical VTs inducible at endpoint testing within the HD Grid
group (3%). It is plausible that the lower numbers of non-
clinical VTs inducible at endpoint testing in the Duodeca
group (8%) as compared to the HD Grid (21%), Pentaray
(41%), and PbyP (66%) groups was a chance effect and this
may have resulted in the higher than expected rate of complete
elimination of all clinical and non-clinical VTs observed in the
Duodeca group (83%).
There was a significant reduction in the duration of RF
delivered in PbyP RF cases compared to multipolar mapping
cases and this may have been as a result of fewer ablation
targets identifiable in the RF group, despite no difference in
LV EF and VT substrate. This resulted in shorter procedure
times with the PbyP RFmapping group. It is plausible that the
ablation delivery to HD Grid mapped substrate is targeted
more effectively towards the arrhythmogenic substrate.
HD Grid mapping resulted in a significant reduction in
ATP and/or appropriate shocks compared to other mapping
catheters. We observed no difference in device detected rates
of asymptomatic NSVT or all cause death. Comparison of
long-term outcomes based on mapping catheter type shows
a step-wise improvement in freedom from recurrent ATP or
shock, such that multipolar mapping with the Pentaray or
Duodeca catheter was superior to PbyP RF catheter mapping,
whereas mapping with the HD Grid portended the best long-
term results. The explanation for this step-wise improvement
in outcome is likely to be multifactorial and due to the unique
electrode grid design that facilitates rapid high density map-
ping and mitigates the effects of wavefront propagation on
local electrogram amplitude and characteristics [13, 25].
Indeed, in 13 large VT ablation [8, 26–37] studies the type
of mapping catheter is mentioned in the methodologies in 8
studies [8, 28, 30, 31, 33–35, 37] and only 2 of these studies
[8, 30] mentioned the use of multipolar mapping catheters.
Various mapping strategies are described with studies using
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exclusive or combinations of substrate, entrainment, and
pacemapping as well as targeting LAVA and DEEP poten-
tials, resulting in a range of acute procedural success rates
from 41 to 94%. More recently, the use of high-density map-
ping catheters in defining VT isthmus sites using a novel re-
entry vulnerability index (RVI) has been described. Despite
this index correlating with pacemap and entrainment map de-
fined VT isthmus sites in 72% of VTs, 16 month follow-up
resulted in a 50% recurrence rate [38]. The advantages of HD
Grid mapping versus PbyP RF mapping in focal arrythmias
with normal structural hearts has been recently highlighted,
with significantly earlier electrograms at the site of successful
ablation and a significant reduction in map and procedure
times [39]. However, neither of these positive outcomes im-
pacted on acute procedural or long-term success. A smaller
study of 22 patients evaluating the HD Grid catheter in ven-
tricular arrythmias including 15 patients with structural heart
disease VT reported acute procedural success rates of 86%
[40]. Patients underwent short-term follow-up at a median of
145 days with a total cohort ventricular arrhythmia recurrence
of 27%. The authors did not report short-term outcomes spe-
cifically for the structural heart disease patients. A strength of
our study is the systematic application of the UHCW VT
ablation workflow which applies complementary multiple
mapping strategies using high density mapping catheters
which resulted in 29/73 (40%) patients suffering recurrent
ATP, shock or death in the total cohort, compared to only 6/
33 (18%) in the HDGrid group, with long-term follow-up at a
mean of 12 ± 8months (372 ± 234 days). A total of 14 patients
died during the follow-up period (HD Grid 5; Pentaray 3;
Duodeca 5; RF 1). One death was arrhythmic, 24 days post-
ablation in a patient with hypertrophic cardiomyopathy (EF
22%) who underwent combined endocardial and epicardial
ablation with complete elimination of all on-table VTs. The
remainder included 6 non-cardiac and 7 deaths due to progres-
sive heart failure.
The long-term outcome for patients undergoing VT abla-
tion targeting late potentials varies depending on the scar sub-
strate. Late potentials are more commonly observed in ische-
mic cardiomyopathy (ICM) than in non-ischemic cardiomy-
opathy (NICM), and it has been shown that approaches incor-
porating late potential ablation and pace mapping have limited
success in patients with NICM compared with ICM [41, 42] .
This indeed may incur potential bias and limitations of HD
Grid substrate mapping in NICM. The number of patients
with NICM within our study was small and we did not ob-
serve a difference in outcome within HD Grid mapped NICM
cases compared to ICM outcomes. A potential explanation is
that the UHCWmapping strategy is based on DEEP potential
mapping and VT site of origin (critical isthmus) mapping
which differed from the substrate mapping approaches de-
scribed by Nakahara et al. Furthermore, the mapping catheters
used by Nakahara et al. were limited to PbyP Navi-Star
catheters (3.5 or 4 mm tip electrode, Biosense-Webster) and
multipolar mapping with the Duodeca catheter. The HD Grid
provides high density sampling, improved signal resolution
afforded by small closely spaced bipolar recordings that min-
imizes the need for catheter positioning, with the unique elec-
trode grid design that mitigates the effects of wavefront prop-
agation on local electrogram amplitude and characteristics.
These catheter properties would additionally contribute to
the improved outcomes in NICM patients. Our overall cohort
survival rates free of ATP or shock are similar to previously
reported studies; however, we have shown a significant im-
provement with HD Grid mapping strategies.
4.4 Limitations
The main limitation of our paper is that the study population
was not randomized. We did not perform a qualitative assess-
ment of the substrate and activation maps obtained with the
different mapping catheters. Such comparison would have
required each patient to undergo mapping with all 4 mapping
catheters and a detailed analysis of maps generated with iden-
tical substrate. This comparison, however ideal, would have
unnecessarily increased procedure time and was economically
unviable.
The field of VT mapping and ablation has grown exponen-
tially with novel methods of identifying the VT site of origin
with newer technologies. Methods such as RVI, MRI-assisted
channel identification, and non-contact mapping technologies
were not assessed in this study.
Finally, an assessment of lesion durability such as compar-
isons of impedance change, force-time integral, or ablation
lesion indices were not performed. This important aspect of
VT mapping and ablation forms the basis of further
investigation.
5 Conclusions
A wide variety of mapping catheters can be used with an
armamentarium of strategies to define VT ablation targets.
We have shown a step-wise improvement in survival free
from ICD therapies as the density of mapping capability in-
creases. By using a high-density mapping catheter and com-
bining complementary mapping strategies in a strict
workflow, long-term clinical outcomes are improved.
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